Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy showed no clear difference in adverse events at 3 to 12 months' compared with antibiotics alone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Adverse events: other · Adults (general population)
1 finding from 1 review
Sexual adverse events
Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).
1 finding from 1 review
Sexual adverse events
Naftopidil showed no clear difference in sexual adverse events compared with tamsulosin (alpha‐blocker) (low certainty).
1 finding from 1 review
Sexual adverse events
Silodosin probably leads to higher sexual adverse events compared with tamsulosin (moderate certainty).
1 finding from 1 review
Sexual adverse events
Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).
1 finding from 1 review
Sexual adverse events
Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).
1 finding from 1 review
Sexual adverse events
Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing pancreaticoduodenectomy
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing distal pancreatectomy
1 finding from 1 review
Sexual adverse events
1 finding from 1 review
Sexual adverse events
1 finding from 1 review